drugset / Trial / NCT02538003

To Evaluate the Effect of Food on Pharmacokinetics(PK), Phase I Clinical Study of LCB01-0371

NCT02538003

Phase 1 Completed 30 enrolled LigaChem Biosciences, Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to assess safety, tolerability of LCB01-0371 after fasting/non-fasting food taken in healthy male subjects.

Timeline

Start
2015-09
Primary completion
2015-12
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Delpazolid Small molecule 800 mg

Indications

No indication recorded.